Browsing by Author "Hartavi, Mustafa"

Now showing 1 - 13 of 13

Efficacy of sunitinib in patients with imatinib-resistant gastrointestinal stromal tumors
(Derman Medical Publ, 2014-07-01) Çubukcu, Sinem; Kanat, Özkan; Çubukcu, Erdem; Ölmez, Ömer Fatih; Canhoroz, Mustafa; Avcı, Nilüfer; Hartavi, Mustafa; Deligönül, Adem; Seyhan, Serdar; Ayyıldız, Aylin; Taşdemir, Ünal; Manavoğlu, Osman; ÇUBUKÇU, SİNEM; Kanat, Özkan; ÇUBUKÇU, ERDEM; Ölmez, Ömer Fatih; Canhoroz, Mustafa; Avcı, Nilüfer; Hartavi, Mustafa; DELİGÖNÜL, ADEM; Seyhan, Serdar; Ayyıldız, Aylin; Taşdemir, Ünal; Manavoğlu, Osman; Uludağ Üniversitesi/Tıp Fakultesi/İç Hastalıkları Anabilim Dalı,; Uludağ Üniversitesi/Tıp Fakultesi//Tıbbi Onkoloji Bilim Dalı.; JJB-0254-2023; JRU-4028-2023; JGT-4101-2023; DJG-4827-2022; CJW-6018-2022; CCT-7946-2022; CUI-5353-2022; JHC-1731-2023; DSI-5869-2022; KGG-2754-2024; KBV-2934-2024; FLP-9613-2022
Aim: In this study, the efficacy of sunitinib in patients with imatinib-resistant gastrointestinal stromal tumors (GISTs) was investigated. Material and Method: A total of 11 imatinib-resistant GIST patients who have sufficient information about their medical treatment and outcome were retrospectively analyzed. Results: Partial response was observed in only two patients, and five patients achieved stable disease. Progression free survival and overall time was 8.8 months and 12 months, respectively. Sunitinib was relatively well tolerated. Almost all patients experienced one or more treatment-related adverse event. Discussion: Based on our limited experience, we concluded that sunitinib is reasonable treatment option for patients with imatinibresistant GIST.
General characteristics of male breast cancer patients in Bursa region
(Aves, 2012-07-01) Avcı, Nilüfer; Balcı, Mehmet Ali; Esen, İrfan; Tandoğan, Gülen; Merter, Mustafa; Çubukcu, Erdem; Ölmez, Fatih; Coşkun, Belkıs Nihan; Hartavi, Mustafa; Tolunay, Şahsine; Avcı, Nilüfer; Balcı, Mehmet Ali; Esen, İrfan; Tandoğan, Gülen; Merter, Mustafa; ÇUBUKÇU, ERDEM; Ölmez, Fatih; COŞKUN, BELKIS NİHAN; Hartavi, Mustafa; TOLUNAY, ŞAHSİNE; Uludağ Üniversitesi/Tıp Fakültesi/Medikal Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0003-1465-7153; AAI-1612-2021; ABD-7124-2020; AAG-7155-2021; ABI-4413-2020; CCT-7946-2022; DYT-8587-2022; DFP-9003-2022; JGT-4101-2023; JGV-7746-2023; CUI-5353-2022
Introduction: Male breast cancer constitutes less than 1% of all cases of breast cancer. In this study, we analyzed clinical and pathological features of male breast cancer cases, which had been followed up and treated at our institution.Material and Method: The data regarding the main clinicopathological features of the male breast cancer patients were retrieved from the patients' records retrospectively.Results: A total of 16 patients were included in the analysis with a median age of 60 (41-75). The most common cell type was infiltrating ductal carcinoma, comprising 81.3 % of all cases. Most patients were staged as locally advanced (50% - stage 3) at the time of diagnosis. Estrogen and/or progesterone receptor positivity were found in 13 patients (81.3%). HER2 status could be examined in 9 patients, and 4 patients (25%) found to be positive for HER2 overexpression. Overall survival was 3(1-12) years and disease-free survival was 2 (1-8) years.Discussion: Despite the increasing knowledge about breast cancer in women, little is known in case of male breast cancer management. Therefore, there is a strong need to perform randomized studies for the treatment of male breast cancer.
The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme
(Elsevier, 2013-09) Ölmez, Ömer Fatih; Çubukçu, Erdem; Evrensel, Türkkan; Kurt, Mera; Avcı, Nilüfer; Tolunay, Şahsine; Bekâr, Ahmet; Deligönül, Adem; Hartavi, Mustafa; Alkis, Nihan; Manavoǧlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Nöropatoloji Bölümü.; Uludağ Üniversitesi/Tıp Fakültesi/Nöroşirürji Bölümü.; 0000-0003-1637-910X; 0000-0002-9732-5340; AAI-1612-2021; AAA-3961-2020; AAJ-1027-2021
Immunohistochemical expression of human epidermal growth factor receptor (HER)-4 and prognosis in patients with metastatic breast cancer
(Imprimatur Publications, 2016) Deligönül, Adem; Evrensel, Türkkan; Avcı, Nilüfer; Uğraş, Nesrin; Türe, Mehmet; Çubukçu, Erdem; Hartavi, Mustafa; Ölmez, Ömer Fatih; Kurt, Ender; Tolunay, Şahsine; Kanat, Özkan; Manavoğlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Genetik Anabilim Dalı.; 0000-0002-9732-5340; 0000-0002-5771-7649; ESM-4544-2022; AAJ-1027-2021; CCT-7946-2022; AAH-2716-2021; ECY-8582-2022; ETP-1691-2022; CUI-5353-2022; DJG-4827-2022; DAS-3088-2022; AAI-1612-2021; CYM-0930-2022; FLP-9613-2022; 37088030300; 6603942124; 55390409800; 55386535600; 6602186133; 53986153800; 55370753300; 26435400000; 7006207332; 6602604390; 55881548500; 6602587152
Purpose: The clinical value of HER4 - a cell surface receptor that belongs to the human epidermal growth factor receptor family - for predicting survival outcomes in patients with breast cancer remains controversial. Herein, we sought to investigate the prognostic significance of HER4 immunohistochemical expression with respect to progression-free survival (PFS) and overall survival (OS) in Turkish patients with metastatic breast cancer (MBC).Methods: MBC patients (N=45; mean age=50.5 +/- 12.7 years) were consecutively enrolled between 2000 and 2006 in the Department of Oncology at the Uludag University Medical Center, Bursa, Turkey. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded sections. The predictive value of HER4 expression was investigated by multivariate analysis after allowance for potential confounders.Results: The mean PFS in the study participants was 11.35 months (range:1-50), whereas the median OS was 22.18 months (range:1-76). The mean PFS in patients with a HER4 immunohistochemical score of 0, 1+, 2+, and 3+ was 11.0 +/- 4.8, 11.3 +/- 7.7, 11.7 +/- 8.1, and 10.4 +/- 7.4 months, respectively (p=0.99). The mean OS in patients with a HER4 score of 0, 1+, 2+, and 3+ was 13.3 +/- 6.8, 25.6 +/- 10.8, 22.9 +/- 10.7, and 13.5 +/- 9.9, months, respectively (p=0.44). The results of multivariate Cox regression analysis indicated that the presence of visceral metastases was the only independent prognostic factor for both OS (HR=3.01, 95% CI=1.56-3.99, p <0.01) and PFS (HR=2.91, 95% CI=1.51-3.78, p <0.01).Conclusion: HER4 immunohistochemical expression is not an independent predictor of OS and PFS in Turkish MBC patients.
Investigation of FGFR4 (Gly388Arg) gene Polymorphism in primary lung cancer Patients
(Kamla-Raj Enterprises, 2015-03-01) Türe, Mehmet; Yakut, Tahsin; Deligönül, Adem; Karkucak, Mutlu; Sağ, Şebnem Özemri; Hartavi, Mustafa; Çubukcu, Erdem; Gülten, Tuna; Evrensel, Türkkan; Türe, Mehmet; Yakut, Tahsin; DELİGÖNÜL, ADEM; ÖZEMRİ SAĞ, ŞEBNEM; Hartavi, Mustafa; ÇUBUKÇU, ERDEM; Gülten, Tuna; EVRENSEL, TÜRKKAN; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Genetik Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0002-9732-5340; AAJ-1027-2021; AAH-8355-2021; ECY-8582-2022; GIS-1493-2022; ESM-4544-2022; CUI-5353-2022; ETP-1691-2022; EYU-9227-2022
Several studies have shown relationships between predisposition to various types of cancer and polymorphisms of the fibroblast growth factor receptor 4 (FGFR4) gene. In the present study, researchers investigated the relationship between primary lung cancer and (PLC) FGFR4 Gly388Arg polymorphism in regard to tendency, histopathologic sub-type, early onset, and metastatic status. The present study included 124 PLC patients and 100 healthy controls. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to identify gene polymorphism of FGFR4 Gly388Arg. Statistical significance was considered when p < 0.05, and a statistically significant difference was not found in FGFR-4 polymorphism between the patient group and control group in regard to tendency, histopathologic sub-type, early onset, and metastatic status (p > 0.05). The findings in this study demonstrated that there was no relationship between polymorphism of FGFR4 Gly388Arg gene and PLC. However, these results should be confirmed in larger studies and in specific histopathological sub-types of PLC.
Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer
(Imprimatur Publications, 2015-01-01) Ulaş, Arife; Avci, Nilufer; Deligonul, Adem; Tolunay, Sahsine; Cubukcu, Erdem; Olmez, Omer Fatih; Hartavi, Mustafa; Kurt, Ender; Evrensel, Turkkan; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Tıbbi Onkoloji Bilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Patoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.; 0000-0003-1094-5772; 0000-0002-3669-6391; 0000-0002-9038-0515; 0000-0002-0070-0889; 0000-0001-7934-7039; 0000-0002-5446-1254; 0000-0002-9732-5340; CCT-7946-2022; ESM-4544-2022; AAI-1612-2021; ETP-1691-2022; DJG-4827-2022; CUI-5353-2022; DAS-3088-2022; AAJ-1027-2021; 55390409800; 37088030300; 6602604390; 53986153800; 26435400000; 55370753300; 7006207332; 6603942124
Purpose: The impact of neoadjuvant chemotherapy (NACT) on immunohistochemical markers in breast cancer specimens remains controversial. We designed the current study to investigate the potential changes in estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67 expression before and after NACT in a cohort of Turkish patients with breast cancer. Methods: This research was designed as a prospective, observational study of 100 consecutive patients with breast cancer (mean age 47.8 11.4 years) who were scheduled to undergo anthracycline- and/or taxane-containing NACT before attempting cytoreductive surgery at the Department of Oncology of the Uludag University Medical Center, Bursa, Turkey. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded specimens. Results: Changes in immunohistochemical markers before and after NACT were only significant for HER-2 and Ki-67. More specifically, the number of HER-2-positive specimens decreased front 21 before NACT to 8 after NACT (p<0.001). Similarly, the number of tumor samples positive for Ki-67 decreased significantly from 65 to 24 after NACT (p<0.001). Mean pre- and post-treatment tumor grades of differentiation before and after NACT were 2.56 +/- 0.67 and 2.37 +/- 1.07, respectively (p<0.05). We did not find any significant associations between baseline ER, PR, HER2, and Ki-67 expression with both overall survival (OS) and disease-free survival (DFS). Conclusion: Our study suggests that NACT reduces the expression of HER2 and Ki-67 in breast cancer specimens. The significance of NACT-induced changes in the immunohistochemical expression of HER2 and Ki-67 in patients with breast cancer should be further studied in future translational and clinical research.
No association between the SOCS-1 −1478CA/del polymorphism and ulcerative colitis in Turkish subjects
(Springer, 2014-06-19) Hartavi, Mustafa; Nak, Selim Giray; Oral, Haluk Barbaros; Deligönül, Adem; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı.; 0000-0003-0463-6818; K-7285-2012; 55370753300; 6603336505; 7004498001; 37088030300
Suppressor of cytokine signaling (SOCS)-1 is an essential regulator of many cytokine signaling pathways, including those upregulated in the inflamed colonic mucosa of patients with ulcerative colitis. We sought to investigate whether the functional SOCS-1 -1478CA > del polymorphism is associated with UC susceptibility and its disease phenotype in a Turkish clinical sample. A total of 104 subjects were enrolled in a case-control study (52 UC cases and 52 controls). The SOCS-1 -1478CA > del polymorphism was genotyped using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The odds ratio of the del allele for UC relative to the CA allele was not significant (OR = 1.04, 95 % CI 0.59-1.82, P = 0.88). These results did not change after adjustment for age and sex in multivariable regression analysis (OR = 1.07, 95 % CI 0.42-1.69, P = 0.73). When the SOCS-1 -1478CA > del polymorphism was analyzed among UC patients according to continuous disease and non-continuous disease, the del allele was not associated with disease recurrence (OR = 1.56, 95 % CI 0.78-4.56, P = 0.83). Furthermore, when we divided UC patients into two groups according to a previous history of colectomy, we found no significant effect of the del allele (OR = 1.94, 95 % CI 0.55-5.61, P = 0.91). Taken together, these findings suggest that SOCS-1 -1478CA > del polymorphism does not contribute to UC susceptibility and its disease phenotype in Turkish subjects.
Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer
(Imprimatur Publications, 2013-01-29) Ölmez, Fatma; Çubukçu, Erdem; Kanat, Özkan; Ölmez, Ömer Fatih; Kabul, Selva; Canhoroz, Mustafa; Avcı, Nilüfer; Deligönül, Adem; Hartavi, Mustafa; Çubukçu, Sinem; Kurt, Ender; Evrensel, Türkkan; Gökgöz, Şehsuvar; Manavoǧlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.; 0000-0002-9732-5340; AAJ-1027-2021; DJG-4827-2022; ETP-1691-2022; CYM-0930-2022; CAH-9737-2022; CJW-6018-2022; CCT-7946-2022; ESM-4544-2022; CUI-5353-2022; CMF-4464-2022; DAS-3088-2022; EXK-4525-2022; FLP-9613-2022; 53986153800; 55881548500; 55779185600; 56113027300; 52663246200; 55390409800; 37088030300; 55370753300; 55778484600; 7006207332; 6603942124; 6603238737; 6602587152
Purpose: To determine the prognostic significance of estrogen receptor (ER), progesterone receptor (PR), HER2/neu, Ki-67, and nm23 immunohistochemical expression with respect to progression free survival (PFS) and overall survival (OS) in Turkish patients with invasive breast cancer (IBC). Methods: Patients with IBC (n = 81; mean age = 51.9 ± 11.1 years) were prospectively enrolled at the Department of Oncology, Uludag University Medical Center, Bursa, Turkey. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections. Results: We did not find any significant association between immunohistochemical expression of ER, PR, HER2/neu, Ki-67, and nm23 and the baseline characteristics of IBC patients. The median patient PFS was 30 months (range 22-45), and the median OS was 32 months (range 23-46). Stratification of the patient population according to nm23 immunohistochemical expression revealed a statistically significant difference in terms of both OS (p < 0.05) and DFS (p < 0.05). Multivariate Cox regression analysis indicated that tumor grade, axillary lymph node status, and nm23 immunohistochemical expression were the 3 main independent prognostic factors for PFS and OS in IBC patients. Conclusion: Reduced nm23 immunohistochemical expression is an independent negative prognostic factor for OS and PFS. Patients with negative nm23 expression may require a more intensive follow-up.
Prognostic significance of human epidermal receptor (HER)-3 immunohistochemical expression in patients with metastatic breast cancer
(Asian Pacific Organization for Cancer Prevention, 2013) Ölmez, Fatma; Ölmez, Ömer Fatih; Evrensel, Türkkan; Çubukçu, Erdem; Uğraş, Nesrin; Avcı, Nilufer; Canhoroz, Mustafa; Deligönül, Adem; Hartavi, Mustafa; Çubukçu, Sinem; Tolunay, Şahsine; Kurt, Ender; Kanat, Özkan; Manavoğlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0002-9732-5340; AAJ-1027-2021; AAH-2716-2021; AAI-1612-2021; DJG-4827-2022; ETP-1691-2022; CCT-7946-2022; CJW-6018-2022; ESM-4544-2022; CUI-5353-2022; CMF-4464-2022; DAS-3088-2022; CYM-0930-2022; FLP-9613-2022; 26435400000; 6603942124; 53986153800; 55386535600; 55390409800; 52663246200; 37088030300; 55370753300; 55778484600; 6602604390; 7006207332; 55881548500; 6602587152
Background: Previous reports have shown that human epidermal receptor (HER)-3 overexpression may be associated with poor prognosis in patients with breast cancer, but results have been conflicting. In this study, we sought to investigate the prognostic significance of HER-3 immunohistochemical expression in patients with metastatic breast cancer. Methods: We retrospectively analyzed HER-3 immunohistochemical expression profiles in 45 paraffin-embedded specimens from patients who had been treated between 1996 and 2006 in the Department of Oncology of the Uludag University School of Medicine, Bursa, Turkey. Membranous or cytoplasmic dominant expression patterns of HER-3 were analyzed using the Rajkumar score and a cytoplasmic 4-point scoring system, respectively. Progression-free survival (PFS) and overall survival (OS) served as the main outcome measures. Results: The median PFS in the study participants was 9 months (interquartile range: 4.5-13 months), whereas the median OS was 20 months (interquartile range: 7.5-28 months). Categorization of the patient population according to HER-3 positive immunohistochemical expression did not reveal any statistically significant difference in terms of both PFS (p=0.70) and OS (p=0.81). The results of multivariable Cox regression analysis indicated that tumor size was the only independent predictor of PFS, whereas estrogen and progesterone receptor status was independently associated with OS. Conclusions: HER-3 immunohistochemical expression did not correlate with outcomes in Turkish patients with metastatic breast cancer. Although our results suggest that HER-3 expression in cancer specimens is not of prognostic significance, further prospective studies are warranted to confirm these results.
Relationship between glycemic control, microalbuminuria and cognitive functions in elderly type 2 diabetic patients
(Taylor & Francis Ltd, 2014-06-23) Gül, Bülent Cuma; Öz Gül, Özen; Cander, Soner; Eroğlu, Ayça; Hartavi, Mustafa; Keni, Nermin; Bayındır, Ayşenur; Ersoy, Canan Özyardımcı; Ertürk, Erdinç; Tuncel, Ercan; İmamoğlu, Şazi; Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0003-2467-9356; A-7063-2018; AAI-1005-2021; AAH-8861-2021; AAJ-6536-2021; 23988796000; 26040787100; 25027068600; 24437934700; 55370753300; 56341244400; 56340081700; 6701485882; 7005488796; 7006929833; 6602297533
Aim: The prevalence of diabetes is increasing in elderly populations, and is thought to be an important risk factor for cognitive dysfunction in this age group. Methods: The study included 104 patients aged over 60 years who were followed-up for type 2 diabetes for at least 6 months, in addition to 44 controls. Glycemic parameters, microangiopathic complications, microalbumin elimination, and the Standardized Mini Mental State Examination (SMMSE) scores were used as indicators of cognitive function. Results: The SMMSE scores of diabetic patients were significantly lower than the control group (p<0.05). The average SMMSE score for normoalbuminuric diabetic patients was 22.36 +/- 4.66, compared with 22.61 +/- 4.90 for the microalbuminuria patients (p = 0.84). A positive correlation was found between SMMSE scores and patients' hemoglobin values and education levels, whereas a negative correlation was noted between SMMSE scores and systolic and diastolic blood pressures and hemoglobin A1c levels (p<0.05). Patients with diabetic neuropathy, a microvascular complication of diabetes, were found to have significantly lower SMMSE scores (p = 0.011). Conclusion: Elderly diabetic patients showed decreased cognitive function compared to volunteers. No relationship was established between microalbuminuria and cognitive functions, although diabetic neuropathy was found to be related to decreased cognitive function.
Serum uric acid is not associated with diabetic nephropathy in patients with type 2 diabetes
(Carbone Editore, 2015-03-30) Gül, Cuma Bülent; Yıldız, Abdülmecit; Gül, Özen Öz; Hartavi, Mustafa; Cander, Soner; Eroğlu, Ayça; Keni, Nermin; Bayındir, Ayşenur; Ersoy, Alparslan; Ersoy, Canan; YILDIZ, ABDULMECİT; ÖZ GÜL, ÖZEN; Hartavi, Mustafa; CANDER, SONER; Eroğlu, Ayça; Keni, Nermin; Bayındır, Ayşenur; ERSOY, ALPARSLAN; ERSOY, CANAN; Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.; 0000-0002-0710-0923; AAI-1005-2021; AAH-5054-2021; AAH-8861-2021; HIG-9032-2022; CUI-5353-2022; HUR-0563-2023; COU-0270-2022; FEA-3241-2022; CFL-1808-2022
Introduction: Although epidemiologic studies suggest a link between serum uric acid (SUA) and vascular complications in diabetes, the relationship of uric acid with diabetic nephropathy remains unclear. We aimed to investigate the relationship between SUA and the degree of albuminuria in patients with type 2 diabetes (T2D).Materials and methods: The cross-sectional study included 223 T2D patients. Nephropathy was graded as follows: nor-moalbuminuria, urinary albumin excretion (UAE) less than 30 mg per gram of creatinine (mg/g Cr); microalbuminuria, 30 to 300 mg/g Cr; or macroalbuminuria, more than 300 mg/g Cr. SUA was measured using a uricase-peroxidase enzymatic method.Results: The degree of nephropathy was as follows: normoalbuminuria in 163 subjects, microalbuminuria in 45 subjects, and macroalbuminuria in 15 patients. SUA did not differ significantly according to the degree of albuminuria. In addition, multivariable analysis demonstrated that hyperuricemia was not an independent predictor of neither microalbuminuria nor macroalbuminuria in T2D patients.Conclusion: Hyperuricemia does not reflect the severity of nephropathy in T2D patients.
The SOCS-1-1478CA/del polymorphism is not associated with colorectal cancer or age at onset in Turkish subjects
(Asian Pacific Organization Cancer Prevention, 2013) Hartavi, Mustafa; Kurt, Ender; Oral, Haluk Barbaros; Ölmez, Ömer Fatih; Çubukçu, Erdem; Deligönül, Adem; Avcı, Nilüfer; Manavoǧlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Bölümü.; 0000-0003-0463-6818; K-7285-2012; 55370753300; 7006207332; 7004498001; 26435400000; 53986153800; 37088030300; 55390409800; 6602587152
Background: Suppressor of cytokine signaling (SOCS)-1 acts as a key regulator of many cytokine signaling pathways and its abnormal expression has been identified in several human malignancies, suggesting potential roles in carcinogenesis. The aim of this study was to investigate any association between the functional SOCS-1 -1478CA>del polymorphism and colorectal cancer (CC) as well as age at onset in a Turkish clinical sample. Materials and Methods: A total of 122 subjects were enrolled in this case-control study (70 CC cases and 52 controls). The SOCS-1 -1478CA>del polymorphism was genotyped using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Results: The odds ratio of the del allele for CC relative to the CA allele was not significantly different between the groups (OR=0.71, 95% CI=0.41-1.22, p=0.27). This result did not change after adjustment for age and sex on multivariable regression analysis (OR=0.84, 95% CI=0.59-1.34, p=0.53). When the SOCS-1 -1478CA>del polymorphism was analyzed among CC patients in relation to the age at disease onset, we found no significant differences between subjects with the del/del, CA/del, and CA/CA genotypes. Conclusions: The results of our study did not point towards a major role of the SOCS-1 -1478CA>del polymorphism in the pathogenesis of CC in Turkish subjects.
Ülseratif kolit tanılı hastalarda sitokin sinyal supresör (SOCS)- 1 1478 CA/DEL gen polimorfizminin incelenmesi
(Uludağ Üniversitesi, 2012) Hartavi, Mustafa; Nak, Selim Gİray; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.
Ülseratif kolit, kolonun distalinden proksimaline doğru diffüz mukozal tutulum gösteren, remisyon ve aktivasyonlarla seyreden kronik inflamatuvar bir hastalıktır. İnsidansı ülkemizde ve dünyada giderek artma eğilimindedir. Patogenezi tam olarak aydınlatılamamıştır. Etkilenen kişilerde çevresel faktörler, genetik faktörler ve immun sistemin ilişkisinden kaynaklanan kolon mukozasında kronik inflamatuvar bir süreç gelişmektedir. Ülseratif kolitte gelişen inflamasyonun değişik klinik tablolar sergilemesi immun sistemin aşırı cevap vermesinden olabilir. Mukozal immun sistemdeki bozulmalar aşırı sitokin cevabıyla ortaya çıkan kronik kontrol edilemeyen mukozal inflamasyona yol açar. İmmun sistemin regülasyonunu sağlayan ve bu ölçüsüz cevabı engelleyen önemli proteinlerden biri sitokin sinyal supresör (SOCS-1 ) proteinidir. SOCS-1 sitokin sinyal iletiminin doğal inhibitörüdür. SOCS-1 fonksiyonunu değiştirecek mutasyon ya da polimorfizm neticesinde GİS kanalda gelişen aşırı immun cevaba bağlı olarak inflamatuar süreç meydana gelebilir ve mukozal hasar gelişebilir. SOCS-1 proteininde meydana gelebilecek polimorfizm inflamatuar süreç gelişimine katkıda bulunarak hastalık etyopatogenezinde rol oynuyor olabilir.Biz bu çalışmamızda SOCS-1 gen polimorfizmini, etyopatogenezinde tekrarlayan kronik inflamasyona neden olan baskılanamayan aşırı sitokin cevabının önemli rol aldığı Ülseratif Kolit tanılı hastaların kendi içinde ve sağlıklı kontrol grubu ile karşılaştırarak incelemeyi amaçladık.Çalışmada Ülseratif Kolit tanısı almış hastalarda değişik klinik tabloları (Remisyondaki hastalar, aktivasyondaki hastalar, kollektomili hastalar) ile SOCS-1 1478 CA/DEL polimorfizm ve tiplerinin (majör homozigot CA/CA, minör homozigot DEL/DEL, heterozigot CA/DEL) ilişkisi hastaların kendi içinde ve sağlıklı kontrol grubu ile karşılaştırarak araştırıldı.Çalışma prospektif olarak yürütüldü. Çalışmaya, 52 Ülseratif Kolit tanılı hasta ve 52 sağlıklı kontrol grubu dahil edildi. Çalışmaya katılan hastalarda SOCS-1 1478 CA/DEL gen polimorfizmi, polimeraz zincir reaksiyonu ve restriksiyon fragmanı uzunluk polimorfizmi (PZR-RFLP) yöntemi ile tayin edildi.Ülseratif Kolit tanılı hastalarda SOCS-1 1478 CA/DEL gen polimorfizmi genotipleri sıklığı; CA/CA (Majör homozigot) 24 (%46.2), DEL/DEL (Minör homozigot) 12 (%23.1), CA/DEL (Heterozigot) 16 (%30.8) hastada tespit edildi. Kontrol grubundaki bireylerde ise; CA/CA 23 (%44.2) kişide, DEL/DEL 10 (%19.2) kişide, CA/DEL 19 (%36.5) kişide saptandı. Bu sonuca göre hasta grubunun SOCS-1478 CA/DEL gen polimorfizm genotipleri sıklığı, kontrol grubu bireyleri ile karşılaştırıldığında benzer bulunarak istatisel anlamlılık düzeyine ulaşmadı (p= 0.794).Çalışmamızda Ülseratif Kolit seyri ile SOCS-1 1478 CA/DEL polimorfizmi arasında ilişki saptayamamış olmamız, hasta sayısının azlığından kaynaklanabileceği gibi SOCS1 1478 CA/DEL dışında başka bir SOCS (SOCS-2 -SOCS-7) polimorfizmi ile de ilişkili olabilir.Sonuç olarak; çalışmamız Ülseratif Kolit tanılı hastalarda SOCS-1 gen polimorfizmini araştıran ilk çalışma olması nedeniyle önemlidir. Ancak bu konuda daha kesin bir sonuca varmak için Türkiye' den ve dünyadan daha fazla sayıda vaka içeren çalışmalara ihtiyaç vardır.